Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Prometheus Biosciences

Merck is facing the LOE on Keytruda before the end of the decade, which makes up more than 35% of the company's revenue. The company has an impressive portfolio of assets, but its pipeline is sparse and its valuation is higher.

Merck's Prometheus Acquisition Is A Step In The Right Direction

Merck & Co.'s $10.8 billion acquisition of Prometheus Biosciences Inc., which it announced Sunday, is a strategic positive that will help the drug company diversify its portfolio and reduce the risk of an overreliance on its cancer drug Keytruda, analysts said Monday.

Merck's $10.8 billion takeover of Prometheus is a good strategic move that gives it a foothold in immunology

Merck is acquiring Prometheus Bio in a well-timed $10.8 billion deal ahead of Keytruda's patent loss. The news sent RXDX stock flying Monday.

Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom

Prometheus' PRA023 drug can add 15% to 30% to Merck's long-term earnings once approved, according to Citi analysts.

Merck's $10.8 Billion Prometheus Deal Has Citi Analysts Bullish

Merck & Co Inc (NYSE:MRK) is set to acquire Prometheus Biosciences for $10.8bn in an all-cash deal, as the US drugmaker aims to bolster its pipeline. San Diego-based Prometheus focuses on diseases caused by abnormal immune system activity and is working on a monoclonal antibody treatment for ulcerative colitis, an inflammatory bowel disease.

Merck makes US$11bn swoop for California biotech

Moderna

A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%, the drug makers said Sunday.

Moderna, Merck combo cancer-vaccine treatment shows ‘significant' promise

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection Results from the Phase 2b KEYNOTE-942 trial selected for AACR press program Companies will initiate a Phase 3 study in patients with adjuvant melanoma in 2023, and rapidly expand to additional tumor types, including non-small cell lung cancer CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / April 16, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV). In the overall intention-to-treat population, adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS), and reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.309-1.017]; one-sided p value=0.0266) compared with KEYTRUDA alone.

Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following C

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA® Plus Chemotherapy Significantly Improved OS Compared to Chemotherapy Alone in Patients With Advanced or Unresectable BTC

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer

RAHWAY, N.J. & SAN DIEGO--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.

Merck & Co. is in late-stage talks to acquire Prometheus Biosciences Inc., according to people familiar with the matter, a move that could give the big drugmaker promising immune disease treatments.

Merck in Late-Stage Talks to Acquire Prometheus Biosciences

Merck's (MRK) application seeking approval for Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy for the early treatment of locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was accepted by the FDA.

Merck's (MRK) Keytruda sBLA Accepted by FDA for Gastric Cancer

Merck (NYSE: MRK ) stock is on the move Thursday after the pharmaceutical company got an update from the FDA concerning Keytruda. Keytruda is Merck's anti-PD-1 therapy.

Why Is Merck (MRK) Stock Up Today?

Citigroup upgraded blue-chip pharma giant Merck & Co., Inc. (NYSE:MRK) to "buy" and hiked its price target to $130, citing "materially revised forecasts" for the company's experimental cancer treatment MK-2870.

Blue-Chip Pharma Stock Jumps on Bull Note, FDA Approval

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA KEYNOTE-859 Filing Acceptance

FDA Accepts Application for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Shares of Merck & Co. Inc. MRK rose 1.1% to pace the Dow Jones Industrial Average's DJIA premarket gainers, after Citi Research turned bullish on the drug maker, citing “materially revised forecasts” for cancer treatment MK-2870/SKB-264. Baum raised his rating to buy, after being at neutral since November 2021, and lifted his stock price target by 23.8%, to $130 from $105.

Merck's stock leads the Dow's early gainers after Citi turns bullish, raises price target by 24%

The US Food and Drug Administration has hit pause on patient enrollment for German drugmaker Merck's multiple sclerosis drug candidate evobrutinib after initial lab results indicated liver injury during Phase III studies. Although the FDA's decision only affects two patients, the news sent Merck's Frankfurt-listed shares falling over 6% on Wednesday.

Merck shares fall after US FDA halts new patient enrollment of MS drug candidate trials

Amgen

Cardinal Health

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts - Cardinal Health (NYSE:CAH), Amgen (NASDAQ:AMGN)

Gilead Sciences

Novartis

Pfizer

Sanofi

Walgreens

First-quarter earnings kick off in a big way on Friday with the major banks posting their results.

Why 7 of the Highest-Yielding ‘Strong Buy' Health Care Stocks Are the Absolute Best 2023 Buys

American Express

ConocoPhillips

Macerich

Occidental Petroleum

Simon Property Group

With the goal of generating long-term capital appreciation, the Smead Value Fund (Trades, Portfolio) is known for investing in a concentrated number of stocks that have strong competitive advantages.

Diving Into the Smead Value Fund's Top Holdings as Value Conference Approaches

Microsoft

What do Mike Trout and Microsoft ( MSFT , Financial) have in common?

My 30-30 Club Gets More Exclusive: Microsoft, Merck and 36 More

Merck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals.

Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail

Apple

Boeing

BuildABear

Celsius Holdings

Cisco Systems

Enphase Energy

Intel

McDonald's

Northern Oil and Gas

Procter & Gamble

Tactile Systems

Direxion Daily Utilities Bull 3X Shares

Walmart

Two new Breakout Stocks for Week 15 with better than 10% short-term upside, ETF updates and a Dow 30 Picks. Average cumulative returns for 2023 are +48.5% YTD. Last week peak stock gains were in ATEX +11.62% continuing the streak of 10% gainers. Active ETF portfolio continues up +17.4% YTD.

April MDA Breakout Stocks/ETFs Week 15 - 2023: High-Frequency Gainers To Give You An Edge

Advance Auto Parts

Accenture Plc

Automatic Data Processing

Ball Corp

British American Tobacco

Boston Properties

Cigna

Carlisle Companies

Coterra Energy

Chevron

EOG Resources

Energy Transfer LP Unit

Johnson & Johnson

Lennar

MPLX

Morgan Stanley

NRG Energy

Southern Copper

Stanley Black & Decker

Target

Taiwan Semiconductor Manufacturing

Tyson Foods

This article is part of our monthly series where we highlight five companies that are large-cap, relatively safe, dividend-paying, and are offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks.

5 Relatively Safe And Cheap Dividend Stocks To Invest In - April 2023

News for Merck Stock (MRK)